Service de Pneumologie et Allergologie Pédiatriques, Centre de Ressourcés et de Compétence de la Mucoviscidose, Hôpital Necker Enfants Malades 149 rue de Sévres, INSERM U1151, Institut Necker Enfants Malades, Université Paris Sorbonne, Paris 75743, France.
CF Europe, Joseph Borlélaan 12, 1160 Brussels, Belgium.
J Cyst Fibros. 2021 Nov;20(6):e108-e113. doi: 10.1016/j.jcf.2021.02.009. Epub 2021 Feb 27.
People with cystic fibrosis (pwCF) are central in the development of patient-led assessment tools. Qualitative analysis of a frequently used CF-specific patient-reported outcome measure (PROM) sought patient recommendations for development of a new quality of life (QoL) tool.
We performed an inventory of PROMs, symptom-report and QoL tools used in clinical trials within the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) and in routine clinical practice among Cystic Fibrosis Europe and ECFS members. A qualitative study using cognitive interviews with pwCF and their caregivers reviewed the Cystic Fibrosis Questionnaire (CFQ), the French initial form of the Cystic Fibrosis Questionnaire-Revised (CFQ-R).
Survey results from 33 countries revealed over 70 tools used in routine clinical practice, utilized by clinical specialists (n=124), pwCF/parents/carers (n=49) and other allied health professionals (n=60). The CFQ-R was the main PROM used in clinical trials. The qualitative study enrolled 99 pwCF, 6 to 11 years (n=31); 12 to 18 years (n=38); >18 years (n=30) and 26 parents. Inductive thematic analysis based on the CFQ, revealed 19 key themes. Themes common across all cohorts included burden of treatment, impact of disease on day-to-day life, relationships/family, stress/mood, and nutrition. Themes unique to individual groups included, treatment when not symptomatic for the paediatric group; education/studies and planning for the future for adolescents, impact of anxiety and depression on day-to-day life for adults, and for parents, questions addressing anxiety and their role as carers.
Patient-centeredness is paramount in development of an up-to-date PROM in the era of novel therapies.
囊性纤维化(CF)患者是患者主导评估工具开发的核心。对一种常用 CF 特定患者报告结局测量(PROM)的定性分析寻求了患者对新的生活质量(QoL)工具开发的建议。
我们对欧洲囊性纤维化协会临床试验网络(ECFS-CTN)内临床试验和囊性纤维化欧洲和 ECFS 成员常规临床实践中使用的 PROM、症状报告和 QoL 工具进行了清查。一项使用认知访谈对 CF 患者及其照顾者进行的定性研究,对囊性纤维化问卷(CFQ)和修订后的囊性纤维化问卷(CFQ-R)的法语初始形式进行了审查。
来自 33 个国家的调查结果显示,在常规临床实践中使用了 70 多种工具,由临床专家(n=124)、CF 患者/父母/照顾者(n=49)和其他辅助卫生专业人员(n=60)使用。CFQ-R 是临床试验中主要使用的 PROM。定性研究纳入了 99 名 CF 患者,年龄 6-11 岁(n=31);12-18 岁(n=38);>18 岁(n=30)和 26 名父母。基于 CFQ 的归纳主题分析揭示了 19 个关键主题。所有队列共有的主题包括治疗负担、疾病对日常生活的影响、关系/家庭、压力/情绪和营养。针对特定群体的主题包括儿科群体无症状时的治疗、青少年的教育/学习和未来规划、焦虑和抑郁对成年人日常生活的影响,以及父母对焦虑问题及其作为照顾者的角色的关注。
在新型治疗时代,以患者为中心是开发最新 PROM 的关键。